285 related articles for article (PubMed ID: 23885909)
21. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
Baccarani M; Soverini S; De Benedittis C
Am Soc Clin Oncol Educ Book; 2014; ():167-75. PubMed ID: 24857074
[TBL] [Abstract][Full Text] [Related]
22. The Signature Program: Bringing the Protocol to the Patient.
Kang BP; Slosberg E; Snodgrass S; Lebedinsky C; Berry DA; Corless CL; Stein S; Salvado A
Clin Pharmacol Ther; 2015 Aug; 98(2):124-6. PubMed ID: 25810246
[TBL] [Abstract][Full Text] [Related]
23. The Promise of Genomics and the Development of Targeted Therapies for Cutaneous Squamous Cell Carcinoma.
Harwood CA; Proby CM; Inman GJ; Leigh IM
Acta Derm Venereol; 2016 Jan; 96(1):3-16. PubMed ID: 26084328
[TBL] [Abstract][Full Text] [Related]
24. Histiocytic neoplasms in the era of personalized genomic medicine.
Durham BH; Diamond EL; Abdel-Wahab O
Curr Opin Hematol; 2016 Jul; 23(4):416-25. PubMed ID: 27101528
[TBL] [Abstract][Full Text] [Related]
25. Companion diagnostic testing for targeted cancer therapies: an overview.
Fan YS
Genet Test Mol Biomarkers; 2013 Jul; 17(7):515-23. PubMed ID: 23574530
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.
Eke I; Makinde AY; Aryankalayil MJ; Ahmed MM; Coleman CN
Cancer Lett; 2016 Nov; 382(1):118-126. PubMed ID: 26828133
[TBL] [Abstract][Full Text] [Related]
27. Precision cancer medicine: the future is now, only better.
Tsimberidou AM; Eggermont AM; Schilsky RL
Am Soc Clin Oncol Educ Book; 2014; ():61-9. PubMed ID: 24857061
[TBL] [Abstract][Full Text] [Related]
28. Personalized medicine in gastric cancer: Where are we and where are we going?
Jácome AA; Coutinho AK; Lima EM; Andrade AC; Dos Santos JS
World J Gastroenterol; 2016 Jan; 22(3):1160-71. PubMed ID: 26811654
[TBL] [Abstract][Full Text] [Related]
29. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
30. Personalized targeted therapy for esophageal squamous cell carcinoma.
Kang X; Chen K; Li Y; Li J; D'Amico TA; Chen X
World J Gastroenterol; 2015 Jul; 21(25):7648-58. PubMed ID: 26167067
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
Erman M
J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
[TBL] [Abstract][Full Text] [Related]
32. Implications of intratumour heterogeneity for treatment stratification.
Crockford A; Jamal-Hanjani M; Hicks J; Swanton C
J Pathol; 2014 Jan; 232(2):264-73. PubMed ID: 24115146
[TBL] [Abstract][Full Text] [Related]
33. Novel therapeutic targets in non-small cell lung cancer.
Janku F; Garrido-Laguna I; Petruzelka LB; Stewart DJ; Kurzrock R
J Thorac Oncol; 2011 Sep; 6(9):1601-12. PubMed ID: 21849857
[TBL] [Abstract][Full Text] [Related]
34. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
35. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
Song QB; Wang Q; Hu WG
World J Gastroenterol; 2015 Apr; 21(14):4365-72. PubMed ID: 25892888
[TBL] [Abstract][Full Text] [Related]
36. Personalizing medicine for metastatic colorectal cancer: current developments.
Marques AM; Turner A; de Mello RA
World J Gastroenterol; 2014 Aug; 20(30):10425-31. PubMed ID: 25132758
[TBL] [Abstract][Full Text] [Related]
37. Maurie Markman on the Groundbreaking TAPUR Trial.
Markman M
Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751
[No Abstract] [Full Text] [Related]
38. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
Ruzzo A; Graziano F; Canestrari E; Magnani M
Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
[TBL] [Abstract][Full Text] [Related]
39. Strategies in functional proteomics: Unveiling the pathways to precision oncology.
Favicchio R; Thepaut C; Zhang H; Arends R; Stebbing J; Giamas G
Cancer Lett; 2016 Nov; 382(1):86-94. PubMed ID: 26850375
[TBL] [Abstract][Full Text] [Related]
40. Recent applications of chemosensitivity tests for colorectal cancer treatment.
Yoon YS; Kim JC
World J Gastroenterol; 2014 Nov; 20(44):16398-408. PubMed ID: 25469008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
